Dr. Arkady Mandel said Based on the strength of the clinical data collected and the consistently high safety and efficacy profile of Theralase(TM)'s PDT, I am confident that TLD-1433-based therapy has the potential to become the next gold-standard in the treatment of BCG-Unresponsive patients."